Shanghai Henlius Biotech, Inc. (HKG:2696)
Hong Kong · Delayed Price · Currency is HKD 70.35
+4.80 (7.32%)
Aug 20, 2026, 4:09 PM HKT
Shanghai Henlius Biotech Stock Forecast
Stock Price Forecast
According to 7 analysts polled by S&P Global, Shanghai Henlius Biotech stock has a consensus rating of "Strong Buy" and an average price target of $102.91. The average 1-year stock price forecast is 46.28% higher than the current stock price, while the lowest is $91.46 (+30.01%) and the highest is $119.70 (+70.15%).
Price Target: $102.91 (+46.28%)
Analyst Consensus: Strong Buy
Price Target
Chart* Price targets were last updated on Jun 9, 2026.
Analyst Ratings
The average analyst rating for Shanghai Henlius Biotech stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 8 | 7 | 7 | 6 |
| Buy | 0 | 0 | 0 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst Citic Securities No rating | Citic Securities | Buy Maintains $119.00 | Buy | Maintains | $119.00 | +69.15% | Jun 9, 2026 |
Unknown Analyst CICC No rating | CICC | Buy Maintains $102.91 | Buy | Maintains | $102.91 | +46.28% | Jun 5, 2026 |
Unknown Analyst Shenwan Hongyuan No rating | Shenwan Hongyuan | Buy Maintains $89.00 | Buy | Maintains | $89.00 | +26.51% | Mar 27, 2026 |
Unknown Analyst SWS Res No rating | SWS Res | Buy Maintains $89.00 | Buy | Maintains | $89.00 | +26.51% | Mar 26, 2026 |
| CMB International Securities | CMB International Securities | Buy Maintains $97.75 → $99.78 | Buy | Maintains | $97.75 → $99.78 | +41.83% | Mar 25, 2026 |
Financial Forecast
Revenue This Year
7.73B
from 6.67B
Increased by 15.98%
Revenue Next Year
7.63B
from 7.73B
Decreased by -1.26%
EPS This Year
2.28
from 1.51
Increased by 51.14%
EPS Next Year
1.57
from 2.28
Decreased by -31.28%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.